Glenmark Pharmaceuticals Ltd. has received final approval from the United States Food & Drug Administration (USFDA) for Acetaminophen and Ibuprofen tablets, 250 mg/125 mg (OTC).
The tablets were determined by the FDA to be bioequivalent1 to Advil®2 Dual Action with Acetaminophen Tablets, 250 mg/125 mg (OTC), of Haleon US Holdings, LLC.
Glenmark’s tablets will be distributed in the US by Glenmark Therapeutics Inc., USA.
Glenmark’s current portfolio consists of 195 products authorised for distribution in the US and 52 ANDA’s pending approval with the USFDA. In addition to these internal filings, the company has been exploring external development partnerships to supplement and accelerate the growth of its existing pipeline and portfolio.
The stock traded at ₹1,086.45 on the NSE, up 0.66 per cent as of 9.32 am.
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.